The endometriosis market is expected to grow from $938.0m in 2024 to $2.5 billion in 2034, at a compound annual growth rate ...

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab with chemotherapy, achieved ...

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

Pliant plans to submit the full outcomes from the BEACON-IPF trial for future publication. Credit: Lana Leon/Shutterstock. Pliant Therapeutics has discontinued the bexotegrast development for ...

The ongoing trial is aiming to enrol around 36 IPF subjects. Credit: photobyphotoboy/Shutterstock. GRI Bio has announced encouraging six-week interim safety outcomes ...

The lead investigator is calling on more research into the drug’s safety profile and cost-effectiveness as a treatment for depression. Image credit: My Ocean Production / Shutterstock. A Parkinson’s ...

Tango Therapeutics is focused on advancing precision medicine for cancer treatment. Credit: MacroEcon/Shutterstock. Tango Therapeutics has dosed the first subject in the Phase I/II trial assessing ...

The company has already secured approval for Fintepla in treating Dravet syndrome and Lennox-Gastaut syndrome.

Lipocine has initiated subject dosing in a two-arm, blinded, randomised Phase III trial of LPCN 1154 for postpartum ...

Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi.

Viatris’ presbyopia drug MR-141 (phentolamine ophthalmic solution 0.75%) has met the primary endpoint and all secondary ...

The multiple sclerosis (MS) disease-modifying therapy (DMT) market across the seven major markets (7MM: the US, France, ...